

1 **Heterologous immunisation with vector vaccine as prime followed by mRNA vaccine as boost leads**  
2 **to humoral immune response against SARS-CoV-2, which is comparable to that according to a**  
3 **homologous mRNA vaccination scheme**

4 Ruben Rose <sup>1,†</sup>, Franziska Neumann <sup>2, †</sup>, Olaf Grobe <sup>2</sup>, Thomas Lorentz <sup>2</sup>, Helmut Fickenscher <sup>1</sup>,  
5 Andi Krumbholz <sup>1,2,\*</sup>

6 1 Institut für Infektionsmedizin, Christian-Albrechts-Universität zu Kiel und Universitätsklinikum  
7 Schleswig Holstein, Campus Kiel, Brunswiker Straße 4, D-24105 Kiel, Germany

8 2 Labor Dr. Krause und Kollegen MVZ GmbH, Steenbeker Weg 23, D-24106 Kiel, Germany

9 \* Correspondence: [krumbholz@infmed.uni-kiel.de](mailto:krumbholz@infmed.uni-kiel.de); Tel.: +49-431-22010131

10 † These first authors contributed equally

11 **Abstract**

12 **Background:** The humoral immune response after primary immunisation with a SARS-CoV-2 vector  
13 vaccine (AstraZeneca AZD1222, ChAdOx1 nCoV-19, Vaxzevria) followed by an mRNA vaccine boost  
14 (BioNTech, BNT162b2; Moderna, m-1273) was examined and compared with the antibody response  
15 after homologous vaccination schemes (AZD1222/AZD1222 or BNT162b2/BNT162b2).

16 **Methods:** Sera from 59 vaccinees were tested for SARS-CoV-2 immunoglobulin G (IgG) and virus-  
17 neutralising antibodies (VNA) with four IgG assays, a surrogate neutralisation test (sVNT) and a Vero  
18 cell-based neutralisation test (cVNT) before and after heterologous (n=31 and 42) or homologous  
19 booster vaccination (AZD1222/AZD1222, n=8/9; BNT162b2/BNT162b2, n=8/8). The strength of IgG  
20 binding to separate SARS-CoV-2 antigens was measured as avidity.

21 **Results:** After the first vaccination, prevalence of IgGs antibodies directed against (trimeric) SARS-CoV-  
22 2 spike (S)- protein and its receptor-binding domain (RBD) varied from 55-95 % (AZD1222) to 100%  
23 (BNT162b2), depending on the vaccine used and the SARS-CoV-2 antigen used. The booster vaccination  
24 resulted in 100 percent seroconversion and appearance of highly avid IgG as well as VNA against a  
25 SARS-CoV-2 variant of concern (alpha; B.1.1.7) used as antigen in the cVNT. The results of the sVNT  
26 basically agree with those of our in-house cVNT, but the sVNT seems to overestimate non- and weakly  
27 virus-neutralizing titres. The mean IgG and VNA titres were higher after heterologous vaccination  
28 compared to the homologous AZD1222 scheme.

29 **Conclusions:** The heterologous SARS-CoV-2 vaccination leads to a strong antibody response with anti-  
30 SARS-CoV-2 IgG and VNA titres at a level comparable to that of a homologous BNT162b2 vaccination  
31 scheme. Irrespectively of the chosen immunisation regime, highly avid IgG antibodies can be detected  
32 just two weeks after the second vaccine dose indicating the development of a robust humoral  
33 immunity.

34 **Keywords:** COVID-19; vaccination schemes; immunoglobulin G; maturity process; virus-neutralisation

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

35

## 36 Background

37 Since spring 2020 the pandemic caused by the severe acute respiratory syndrome coronavirus 2 (SARS-  
38 CoV-2) [1] is ongoing and represents a global challenge. The availability of safe and effective  
39 vaccinations are seen as one of the most important pillars in containing the pandemic [2, 3]. Within a  
40 few months, the intensive research activities led to the development of several highly effective SARS-  
41 CoV-2 vaccines [4, 5, 3]. In addition to the induction of cellular immunity, their administration should  
42 stimulate the formation of virus-neutralising antibodies (VNA) that bind to epitopes of the viral spike  
43 (S) protein and its receptor binding domain (RBD) and, thus, prevent the cells from being infected [6,  
44 7, 3].

45 Four SARS-CoV-2 vaccines have received conditional approval in the European Union. These vaccines  
46 are based on two different technologies [8]. For the messenger ribonucleic acid (mRNA) vaccines from  
47 Pfizer/BioNTech (BNT162b2) and Moderna (mRNA-1273), the genetic information for the S-protein  
48 was genetically optimized and the mRNA was packaged in liposomes. After inoculation, the muscle  
49 cells directly expressed this stable and highly immunogenic viral surface protein [2, 6]. In vector  
50 vaccines, replication-deficient human (Ad26.COVID; Janssen) or chimpanzee adenoviruses (ChAdOx1  
51 nCoV-19/AZD1222, Vaxzevria; AstraZeneca, hereinafter referred to as AZD1222) are used to introduce  
52 the genetic information of the SARS-CoV-2 S-protein into the cells, followed by transcription of  
53 deoxyribonucleic acid into mRNA and expression of the S-protein [2, 6].

54 Due to the widespread use of these vaccines, rare and sometimes unexpected side effects have been  
55 reported. Particularly noteworthy are cases of immune thrombotic thrombocytopenia, which  
56 predominantly occurred in women under 50 years of age within one month after the initial vaccination  
57 with AZD1222 [5]. Many of these patients developed cerebral sinus venous thrombosis or splanchnic  
58 vein thrombosis and presented antibodies to platelet factor 4 but without previous exposure to  
59 heparin [5]. Due to this rare but serious side effect, AZD1222 is no longer unreservedly recommended  
60 by the Standing Vaccination Commission (STIKO) of the Robert Koch Institute for individuals under 60  
61 years of age. The STIKO suggests that a vaccination with AZD1222 that has already started should be  
62 completed with an mRNA vaccine [9, 10]. Due to the sharp increase in the delta variant (Pango-lineage  
63 [11] B.1.617.2) in Germany, the STIKO has revised its recommendations once more. Since July 1<sup>st</sup> 2021,  
64 all AZD1222 first vaccinated persons have been recommended to complete the second vaccination  
65 with an mRNA vaccine [12]. Animal experiments indicated very good humoral and cellular immunity  
66 after heterologous vaccination [13, 14]. There is, however, so far only little knowledge on the benefit  
67 of the heterologous vaccination scheme in humans. First results indicated a higher prevalence of short-  
68 lived side effects following the heterologous boost dose compared to the homologous counterpart  
69 [15]. Only a few and mostly preliminary results have so far been published for the immunogenicity of  
70 the AZD1222 / mRNA vaccine regimen [16-19].

71 In this study, we compare the SARS-CoV-2 specific immunoglobulin G (IgG) response after  
72 heterologous immunisation with that elicited by homologous vaccination schedules. We also focus on  
73 the developing anti-SARS-CoV-2 IgG avidity as a parameter for IgG maturity and binding strength.

74 Finally, we use various methods to investigate the development of VNA. Therefore, humoral immunity  
75 induced by vaccines is being extensively studied. We believe that the results obtained in this study will  
76 help to better understand the effects and possibly benefits of a heterologous vaccination regimen.

## 77 **Methods**

78 The anti-S and anti-RBD IgG response after heterologous immunisation with a SARS-CoV-2 vector  
79 vaccine as prime and an mRNA vaccine as boost was compared to that after homologous vaccination  
80 with vector or mRNA vaccines. This setting also includes monitoring of IgG avidity and of virus-  
81 neutralizing capacities. Forty-seven female and twelve male vaccinees with a median age of 31 years  
82 (age span 18 – 61 years) were recruited for this study and gave their informed consent. Forty-two of  
83 them received a heterologous immunisation scheme (N=41, AZD1222/BNT162b2; N=1,  
84 AZD1222/mRNA-1273), while nine and eight vaccinees received a homologous scheme of the vector  
85 vaccine AZD1222 or the mRNA vaccine BNT162b2, respectively. The first blood sample was taken at a  
86 median of 68 days after initial vaccination and the second sample was taken at a median of 15 days  
87 after the second immunisation. For several individuals no serum was available before or after the  
88 booster vaccination (Table 1). The ethics committee of the medical faculty of the Christian-Albrechts-  
89 Universität zu Kiel (Kiel, Germany) approved the study design (D467/20, 16.04.2020, amendment  
90 02.02.2021). We examined the early humoral immune response (other samples obtained a few days  
91 to weeks after the initial immunisation with AZD1222) of most of the subjects in a previous study. In  
92 addition, sera obtained from three vaccinees after the initial immunisation with BNT162b2 (N=2) and  
93 AZD1222 (N=1) have already been tested in frame of the previous study [20]. In this respect, we  
94 consider it justified to include these individuals (and few sera) in the present report and to  
95 demonstrate the results before and after the booster vaccination.

96

### 97 *Anti-SARS-CoV-2 specific IgG immunoassays*

98 The sera were tested with the SERION ELISA agile SARS-COV-2 IgG assay (S-protein as antigen; Institut  
99 Virion\Serion GmbH, Würzburg, Germany) and the Abbott SARS-CoV-2 IgG II Quant assay (RBD as  
100 antigen; Abbott, Wiesbaden, Germany) as described previously [20]. In addition, the LIAISON® SARS-  
101 CoV-2 Trimeric S IgG assay was included as a further assay on a LIAISON® XL system (both Diasorin  
102 S.p.A, Saluggia, Italy). According to the manufacturer, this quantitative chemiluminescence  
103 immunoassay detects IgG directed against the trimeric S-protein and has an excellent clinical sensitivity  
104 and specificity of 98.7% and 99.5%, respectively. The high diagnostic value of this test has also been  
105 demonstrated in a recent seroprevalence study [21]. The results of the three IgG assays were given in  
106 Binding Antibody Units (BAU) per milliliter (BAU / ml), using the manufacturer's conversion factors,  
107 which were based on measurements of the WHO International Standard Anti-SARS-CoV-2  
108 Immunoglobulin (NIBSC code 20-136) [22]. As in our previous studies, we generally rate borderline test  
109 results as positive [23, 20].

### 110 *Anti-SARS-CoV-2 IgG immunoblots including measurement of IgG avidities*

111 All sera were tested with and without avidity reagent in the *recomLine* SARS-CoV-2 IgG assay (Mikrogen  
112 GmbH, Neuried, Germany) as reported previously [23, 20]. The strength of SARS-CoV-2 antigen binding  
113 against the S1-and RBD-subunits of the S-protein and against the nucleoprotein (NP, if detectable) was  
114 assigned to the categories low (= 1), intermediate (= 2), and high (= 3) [20].

#### 115 *Measurement of SARS-CoV-2-neutralising antibodies with two different assays*

116 The sera were examined for their virus-neutralising capacities. First, a surrogate assay was used (TECO®  
117 SARS-CoV-2 Neutralisation Antibody ELISA; TECOmedical AG, Sissach, Switzerland). In this competitive  
118 assay, the human angiotensin-converting enzyme 2 (ACE-2) was attached to the solid phase while  
119 peroxidase-conjugated RBD was present in the liquid phase. If the human serum contained RBD-  
120 specific antibodies, binding of RBD to ACE-2 was prevented. Hence, after washing steps the color  
121 reaction turned out to be weaker compared to a RBD-antibody-free serum sample. According to the  
122 manufacturer, it is assumed from an inhibition of 20% that VNA are present.

123 Second, dilutions of each serum were tested in triplicate in a laboratory-developed Vero cell-based  
124 neutralisation assay (cVNT). This 96-well format cVNT uses an own B.1.1.7 strain from January 2021 as  
125 antigen. A dilution >1:10 was considered likely protective [23, 20].

#### 126 *Data evaluation and statistical calculations*

127 Data were statistically analysed by help of the GraphPad Prism version 9.1.2 software (GraphPad  
128 Software, San Diego, CA, USA). We generally used the Kruskal-Wallis test, an adjusted, non-paired and  
129 non-parametric test. The significance level was defined as 0.05. Furthermore, we calculated the  
130 Pearson correlation coefficient  $r$  to demonstrate the linear correlation between separate data sets.  
131 We used simple logistic regression to determine the probability of detecting VNA with our cVNT as a  
132 function of sVNT results.

## 133 **Results**

### 134 *Composition of the study groups*

135 This study included 59 individuals. Nine and eight of them received a homologous vaccination with  
136 AZD1222 or BNT162b2, respectively, while 42 received a heterologous vaccination. The composition  
137 of the study groups including median age, age-span, gender and time span of blood sampling is  
138 presented in Table 1.

139

140

141

142

143

144

145 **Table 1.** Individuals included in this study


Study groups	Number of individuals after 1 <sup>st</sup> /2 <sup>nd</sup> vaccination	Median age in years	Age span in years	Gender (female/male)	Time span from 1 <sup>st</sup> /2 <sup>nd</sup> vaccination to 1 <sup>st</sup> /2 <sup>nd</sup> serum sampling in days
<i>Heterologous vaccination scheme</i>					
AZD1222/BNT162b2	30/41	27	18-56	33/8	69/16
AZD1222/mRNA-1273	1/1	45	45-45	1/0	64/14
<i>Homologous vaccination scheme</i>					
AZD1222	8/9	41	23-61	6/3	34/14
BNT162b2	8/8	35	23-51	7/1	34/14

146

147 After the first immunisation, all individuals who received an mRNA vaccine developed anti-(trimeric)-  
 148 S and anti-RBD-IgG. The vaccinees who received the AZD1222 had a prevalence of 55.3 % (anti-S IgG),  
 149 76.3 % (anti-trimeric S IgG) and 94.7 % (anti-RBD IgG), respectively. After administration of the second  
 150 dose, the IgG prevalence reached 100% in all groups. The mean anti-SARS-CoV-2 IgG titres varied  
 151 between 39.9 BAU/ml (anti-S IgG; first vaccination in the AZD1222/mRNA group) to 6584 BAU/ml (anti-  
 152 trimeric S IgG; second vaccination in the BNT162b2/BNT162b2 group). After the second vaccine dose,  
 153 an increase in mean anti-SARS-CoV-2 titres was observed in all three study groups and in all assays.  
 154 Compared to the mean anti-SARS-CoV-2 IgG titres after the vector vaccine AZD1222 was administered  
 155 twice, the corresponding titres were 7 to 10 times higher after a heterologous vaccination and even  
 156 10 to 15 times higher according to the homologous BNT162b2 vaccination scheme (Figure 1).

157

158




159

160 **Figure 1:** Anti-SARS-CoV-2 immunoglobulin G response after first (1; empty circles) and second (2; filled circles) immunisation  
 161 with the vector vaccine AZD1222 or the messenger ribonucleic acid (mRNA)-based vaccines BNT162b2 or mRNA-1273. The  
 162 cut-offs for positivity (including borderline results) of anti-trimeric spike (S) IgG assay (A), of the anti-S IgG assay (B), and of  
 163 the anti-RBD IgG assay (C), respectively, are marked by dashed lines. Ns: non-significant; \*:  $p < 0.05$ ; \*\*:  $p < 0.01$ ; \*\*\*:  $p <$   
 164  $0.0001$  (adjusted non-paired and non-parametric test; Kruskal-Wallis test).

165 Next, we examined the development of anti SARS-CoV-2 IgG avidity in an immunoblot. After the first  
 166 vaccination, the mean avidity index was in the low to intermediate range. In contrast, high avidities  
 167 were consistently observed after administration of the second vaccine dose (Figure 2). None of the  
 168 vaccinees showed an IgG reactivity against the NP in the immunoblot (data not shown).


169



170


171 **Figure 2:** Development of anti-SARS-CoV-2 immunoglobulin G avidities after first (1; empty circles) and second (2; filled circles)  
 172 immunisation with the vector vaccine AZD1222 or the messenger ribonucleic acid (mRNA)-based vaccines BNT162b2 or  
 173 mRNA-1273. The measured IgG avidities were assigned to the three categories low (1), intermediate (2) and high (3). Ns: non-  
 174 significant; \*:  $p < 0.05$ ; \*\*:  $p < 0.01$ ; \*\*\*\*:  $p < 0.0001$  (adjusted non-paired and non-parametric test; Kruskal-Wallis test).

175 The virus-neutralising properties of the sera were examined with two different assays. A so-called  
 176 surrogate neutralisation test was used to investigate the extent to which the anti-RBD antibodies that  
 177 may be present in the serum are able to prevent the binding of this S-protein subunit to the human  
 178 receptor ACE2. In addition, a laboratory-developed virus-neutralisation test was used, which is based  
 179 on a B.1.1.7 strain as the antigen. While the majority of the sera in the sVNT were already to be  
 180 regarded as neutralizing after the first vaccination, these samples did not yet show any corresponding  
 181 properties in the cVNT. With both methods, however, an increase in the level of VNA could be detected  
 182 after a second vaccination. There were also marked differences between the three vaccination groups,  
 183 both in the degree of inhibition (sVNT) and in the level of VNA titres (cVNT). Vaccinees who had  
 184 received the vector vaccine only had 13- and 11-fold lower geometric mean VNA titres (1:47) compared  
 185 to individuals immunised heterologously with AZD1222 / mRNA (1:608) or homologously with  
 186 BNT162b2 (1:538), respectively. However, the mean % inhibition of sVNT reached about the same level  
 187 in all three groups (Figure 3). Even though the quantitative results correlate with a Pearson correlation  
 188 coefficient  $r$  of 0.84 well in both tests, it is noticeable that especially non-neutralising sera ( $\leq 1:10$ ) are  
 189 overestimated in the sVNT. This is evidenced by the fact that the cut-off set by the manufacturer is  
 190 only associated with a 4 % probability of detecting VNA in our cVNT (Figure 4).



191

192 **Figure 3:** Development of SARS-CoV-2 neutralising antibodies (VNA) after first (1; empty circles) and second (2; filled circles)  
 193 immunisation with the vector vaccine AZD1222 or the messenger ribonucleic acid (mRNA)-based vaccines BNT162b2 or  
 194 mRNA-1273. A surrogate neutralisation assay (A) and a Vero-cell based virus-neutralisation test (B) using a B.1.1.7 strain were  
 195 used to measure the VNAs. The assay cut-offs are indicated by dashed lines. Ns: non-significant; \*:  $p < 0.05$ ; \*\*:  $p < 0.01$ ;  
 196 \*\*\*\*:  $p < 0.0001$  (adjusted non-paired and non-parametric test; Kruskal-Wallis test).



197

198 **Figure 4:** Correlation of the surrogate neutralisation test (sVNT) results with results obtained by the laboratory developed  
 199 Vero-cell based virus-neutralisation test (cVNT) using a B.1.1.7 strain as antigen (A). The Pearson correlation coefficient  $r$  of  
 200  $\log(\text{reciprocal titre})$  was calculated with 0.84; empty circles; first vaccination; filled circles: second vaccination; red:  
 201 heterologous vaccination with AZD1222/mRNA; green: homologous vaccination with AZD1222; blue: homologous vaccination  
 202 with BNT162b2. Probability of detecting virus-neutralising antibodies (VNA) with the in-house cVNT at a given % inhibition of  
 203 sVNT calculated by logistic regression (B); e.g. at 20% inhibition (black dashed line), 63% inhibition (red dashed line), and at  
 204 85% inhibition of sVNT (red dashed line), the probabilities of detecting VNA with cVNT are 4% (95%CI 1%-16%), 50% (95%CI  
 205 34%-66%) and 83% (95%CI 70%-91%), respectively.



## 206 Discussion

207 Due to the rare but serious side effects after administration of the vector vaccine, in spring 2021 the  
208 STIKO recommended that people under the age of 60 should complete vaccinations that had already  
209 been started with a vector vaccine with an mRNA vaccine [9, 10]. This recommendation was extended  
210 on July 1st, 2021 to all who had already received a primary vaccination with AZD1222 [12]. In the first  
211 quarter of this year, however, only a few animal experimental data were available on the  
212 immunological outcome of the proposed heterologous vaccination scheme [13, 14]. Several preprints  
213 have now appeared on the immunogenicity of the heterologous vaccination scheme in humans [16-  
214 19].

215 We took this general knowledge gap as an opportunity to compare the development of the humoral  
216 immune response after homologous and heterologous vaccination.

217 After the first vaccination, the majority of vaccinees developed anti-trimeric-S, -S, and -RBD IgG  
218 antibodies, respectively. However, their titres varied between the three study groups. The results are  
219 in line with our previous study [20]. It is evident that the anti-SARS-CoV-2 IgG titres are not comparable  
220 between the three assays either. This is probably due to the different antigen preparations. In this  
221 respect, from our point of view, titre comparisons are only possible if they have been measured with  
222 the same assay.

223 The second vaccination resulted in higher titres in all three groups. It was noticeable that significantly  
224 higher anti-SARS-CoV-2 IgG titres were detected after a second vaccination with an mRNA vaccine than  
225 after the vector vaccine AZD1222 was administered again. The increase in anti-S and anti-RBD IgG titres  
226 after a second vaccination with an mRNA vaccine confirms our previous study. Due to the  
227 recommended vaccination interval of 10 to 12 weeks, we did not yet have any data on the  
228 development of the SARS-CoV-2-specific IgG antibodies after the second administration of a vector  
229 vaccine [20]. The absence of NP-specific IgG antibodies in all vaccinated persons can be interpreted as  
230 a hint that they have not had a SARS-CoV-2 infection and were therefore to be regarded as  
231 immunologically naive before the vaccination [20]. It is known that vaccinations lead to particularly  
232 high anti-SARS-CoV-2 IgG titres in convalescents [24]. For these individuals, the recommendation is  
233 that they should receive a vaccine dose about six months after they have been infected [10].

234 After the first vaccination nearly all vaccinees exhibited only low to intermediate avid anti-SARS-CoV-  
235 2 IgG, while after the second vaccine dose IgG of high avidity appeared in all cases. In line with this,  
236 VNA > 1:10 against the prevalent VOC B.1.1.7 strain were observed after second vaccination. The  
237 results confirm our previous study [20]. Marked differences in the level of VNA titres were observed  
238 between individuals re-vaccinated with an mRNA vaccine and those re-vaccinated with a vector  
239 vaccine which is in accordance to previous animal experiments [13]. Basically, the sVNT also showed  
240 the titre increase and evaluated all sera as virus-neutralizing after the second vaccination. However, it  
241 is again noticeable that sera that are not or only weakly virus-neutralising in the in-house cVNT are  
242 already evaluated as neutralising in the sVNT. This result underscores our previous suggestion to raise  
243 the cut-off of the sVNT [20]. Compared to the admittedly very conservative in-house cVNT, a cut-off of

244 over 80% would be desirable. Due to the lack of standardisation of the widespread cVNTs for the  
245 detection of VNA against SARS-CoV-2, this recommendation only applies to our laboratory and cannot  
246 be generalised.

247 The data presented by us on the humoral immune response after heterologous SARS-CoV-2  
248 vaccination are consistent with the few available clinical studies [16, 18, 17, 19]. A recent preprint  
249 reports significant higher anti-S-antibody titres in a group of 26 individuals who first received an  
250 AZD1222 vaccination followed by re-vaccination with BNT162b2 compared to 14 individuals that were  
251 vaccinated twice with BNT162b2. These results were obtained with a total antibody assay which does  
252 not discriminate between IgG and acute phase immunoglobulin M. Nearly four-fold higher virus-  
253 neutralising titres were observed in the AZD1222/BNT162b2 group using a chimeric vesicular  
254 stomatitis virus carrying the S-protein of SARS-CoV-2 VOC B.1.1.7 as antigen. However, data after  
255 homologous vaccination with the vector vaccine are missing in this study [16]. We also observe  
256 differences in the titre level of the VNA in the cVNT. However, these are not to be regarded as  
257 significant in every case.

258 In another preprint [18], differences in the anti-S IgG and VNA titres were not observed after  
259 heterologous vaccination (AZD1222/mRNA) or after homologous vaccination with an mRNA vaccine.  
260 In contrast, both parameters were significantly lower after homologous vaccination with the vector  
261 vaccine [18]. These results are in agreement with our data even if only one IgG assay and one sVNT  
262 were used by this research group.

263 The results of a previously non-peer reviewed single-blind randomised British study, in which the four  
264 possible vaccine combinations of AZD1222 and BNT162b2 were compared with one another, are very  
265 interesting and promising. These researchers report about 9-fold higher mean anti-S IgG titres in  
266 heterologous AZD1222/BNT162b2 vaccinees compared to individuals immunized twice with AZD1222  
267 [19] which is largely in accordance to our results.

268 Only one preprint investigates the development of IgG avidity after heterologous SARS-CoV-2  
269 vaccination in humans [17]. Therein the immune response after heterologous vaccination was  
270 compared with that after homologous vaccination with an mRNA vaccine. However, results obtained  
271 after homologous vaccination with a vector vaccine are missing. The authors demonstrate comparable  
272 IgG responses after the booster vaccination and an increase in VNA (determined by sVNT) as well as  
273 of IgG avidity [17], which is in line to our data and to results of animal experiments [13].

274 It is not yet sufficiently clear why homologous vaccination with the AZD1222 vector vaccine leads to  
275 lower anti-SARS-CoV-2 IgG and VNA titres. A possible explanation could be the immune response to  
276 the adenovirus vector backbone (so called “antivector immunity” [3]).

277 The work presented by us contributes to a better understanding of the humoral immunogenicity of  
278 the heterologous SARS-CoV-2 vaccination regimen. With various assays we monitored the  
279 development of anti S-specific IgG antibodies and make statements about their binding-strength as an  
280 expression of maturity. In addition, with a commercial and an in-house test, we showed that VNA can  
281 be detected after the second vaccination. Important limitations of our report are (i) the heterogeneity

282 of the study groups, (ii) the small group size of individuals who received a homologous vaccination  
283 scheme, (iii) the subjects, who are predominantly in younger to middle adulthood, (iv) the lack of  
284 information on the durability of the detected antibodies, and (v) the missing consideration of cellular  
285 and innate immunity after immunisation. Therefore, among other things, no statements can be made  
286 from our data about the need for further booster vaccinations. In addition, no better protection against  
287 SARS-CoV-2 infections can be derived from the level of the antibody titre *per se*.

288 In summary, the combination of a first vaccination with a vector vaccine followed by a second  
289 administration of an mRNA vaccine leads to a strong humoral immune response, comparable to that  
290 achieved after two vaccinations with an mRNA vaccine. Regardless of the vaccination schedule, all  
291 individuals develop highly avid anti-SARS-CoV-2 IgGs and VNA shortly after the second vaccination.

292

293

294 **Availability of data:** The data presented in this study are available on request from the corresponding  
295 author.

296 **Ethics approval and consent to participate:** The study was conducted according to the guidelines of  
297 the Declaration of Helsinki, and approved by the Ethics Committee of the medical faculty of the  
298 Christian-Albrechts-Universität zu Kiel, Kiel, Germany (D467/20, 16.04.2020; amendment 02.02.2021).  
299 Informed consent was obtained from all subjects involved in the study.

300 **Consent for publication:** Not applicable.

301 **Competing interests:** The companies Diasorin GmbH, Mikrogen GmbH and Tecomedical GmbH  
302 supported this study by providing free or discounted kits. None of the three companies had any  
303 influence on the testing and the interpretation of the results. The authors declare that they have no  
304 competing interests.

305 **Author Contributions:** AK, FN, and RR had full access to all the data in the study and take responsibility  
306 for the integrity of the data and the accuracy of the data analysis. Concept and design: AK. Acquisition,  
307 analysis, or interpretation of the data: all authors. Drafting of the manuscript: AK, HF and RR. Critical  
308 revision of the manuscript for important intellectual content: all authors. All authors have read and  
309 agreed to the published version of the manuscript.

310 **Funding:** This research received no external funding.

311 **Acknowledgments:** The authors would like to thank all subjects for participating in the study.

312

313

## 314 References

315

- 316 1. Hu B, Guo H, Zhou P, Shi ZL. Characteristics of SARS-CoV-2 and COVID-19. *Nat Rev Microbiol.*  
317 2021;19(3):141-54. doi:10.1038/s41579-020-00459-7.
- 318 2. Klasse PJ, Nixon DF, Moore JP. Immunogenicity of clinically relevant SARS-CoV-2 vaccines in  
319 nonhuman primates and humans. *Sci Adv.* 2021;7(12). doi:10.1126/sciadv.abe8065.
- 320 3. Sadarangani M, Marchant A, Kollmann TR. Immunological mechanisms of vaccine-induced  
321 protection against COVID-19 in humans. *Nature Reviews Immunology.* 2021. doi:10.1038/s41577-021-  
322 00578-z.
- 323 4. Krammer F. SARS-CoV-2 vaccines in development. *Nature.* 2020;586(7830):516-27.  
324 doi:10.1038/s41586-020-2798-3.
- 325 5. Cines DB, Bussel JB. SARS-CoV-2 Vaccine-Induced Immune Thrombotic Thrombocytopenia. *N Engl J*  
326 *Med.* 2021;384(23):2254-6. doi:10.1056/NEJMe2106315.
- 327 6. Kyriakidis NC, Lopez-Cortes A, Gonzalez EV, Grimaldos AB, Prado EO. SARS-CoV-2 vaccines strategies:  
328 a comprehensive review of phase 3 candidates. *NPJ Vaccines.* 2021;6(1):28. doi:10.1038/s41541-021-  
329 00292-w.
- 330 7. Creech CB, Walker SC, Samuels RJ. SARS-CoV-2 Vaccines. *JAMA.* 2021;325(13):1318-20.  
331 doi:10.1001/jama.2021.3199.
- 332 8. EU. Safe COVID-19 vaccines for Europeans. 2021. [https://ec.europa.eu/info/live-work-travel-](https://ec.europa.eu/info/live-work-travel-eu/coronavirus-response/safe-covid-19-vaccines-europeans_en)  
333 [eu/coronavirus-response/safe-covid-19-vaccines-europeans](https://ec.europa.eu/info/live-work-travel-eu/coronavirus-response/safe-covid-19-vaccines-europeans_en) en. Accessed 12 May 2021.
- 334 9. STIKO. Stellungnahme der Ständigen Impfkommission zum Zeitpunkt der Gabe eines mRNA-  
335 Impfstoffs nach Erstimpfung mit AstraZeneca Vaccine (Vaxzevria) bei <60-Jährigen. 2021.  
336 [https://www.rki.de/DE/Content/Kommissionen/STIKO/Empfehlungen/Stellungnahme-](https://www.rki.de/DE/Content/Kommissionen/STIKO/Empfehlungen/Stellungnahme-Impfabstand.html)  
337 [Impfabstand.html](https://www.rki.de/DE/Content/Kommissionen/STIKO/Empfehlungen/Stellungnahme-Impfabstand.html). Accessed 12 May 2021.
- 338 10. RKI. Mitteilung der Ständigen Impfkommission beim Robert Koch-Institut Beschluss der STIKO zur  
339 7. Aktualisierung der COVID-19-Impfempfehlung und die dazugehörige wissenschaftliche Begründung.  
340 *Epidemiologisches Bulletin.* 2021;25:3-13.
- 341 11. Rambaut A, Holmes EC, O'Toole Á, Hill V, McCrone JT, Ruis C et al. A dynamic nomenclature  
342 proposal for SARS-CoV-2 lineages to assist genomic epidemiology. *Nature Microbiology.*  
343 2020;5(11):1403-7. doi:10.1038/s41564-020-0770-5.
- 344 12. STIKO. Mitteilung der STIKO zur COVID-19-Impfung: Impfabstand und heterologes Impfschema  
345 nach Erstimpfung mit Vaxzevria (1.7.2021). 2021.  
346 [https://www.rki.de/DE/Content/Kommissionen/STIKO/Empfehlungen/PM\\_2021-07-01.html](https://www.rki.de/DE/Content/Kommissionen/STIKO/Empfehlungen/PM_2021-07-01.html).  
347 Accessed 2 July 2021.
- 348 13. Spencer AJ, McKay PF, Belij-Rammerstorfer S, Ulaszewska M, Bissett CD, Hu K et al. Heterologous  
349 vaccination regimens with self-amplifying RNA and adenoviral COVID vaccines induce robust immune  
350 responses in mice. *Nature Communications.* 2021;12(1):2893. doi:10.1038/s41467-021-23173-1.
- 351 14. He Q, Mao Q, An C, Zhang J, Gao F, Bian L et al. Heterologous prime-boost: breaking the protective  
352 immune response bottleneck of COVID-19 vaccine candidates. *Emerging Microbes & Infections.*  
353 2021;10(1):629-37. doi:10.1080/22221751.2021.1902245.

- 354 15. Shaw RH, Stuart A, Greenland M, Liu X, Van-Tam JSN, Snape MD et al. Heterologous prime-boost  
355 COVID-19 vaccination: initial reactogenicity data. *Lancet*. 2021;397(10289):2043-6.  
356 doi:10.1016/S0140-6736(21)01115-6.
- 357 16. Groß R, Zanoni M, Seidel A, Conzelmann C, Gilg A, Krnavek D et al. Heterologous ChAdOx1 nCoV-  
358 19 and BNT162b2 prime-boost vaccination elicits potent neutralizing antibody responses and T cell  
359 reactivity. *medRxiv*. 2021:2021.05.30.21257971. doi:10.1101/2021.05.30.21257971.
- 360 17. Hillus D, Schwarz T, Tober-Lau P, Hastor H, Thibeault C, Kasper S et al. Safety, reactogenicity, and  
361 immunogenicity of homologous and heterologous prime-boost immunisation with ChAdOx1-nCoV19  
362 and BNT162b2: a prospective cohort study. *medRxiv*. 2021:2021.05.19.21257334.  
363 doi:10.1101/2021.05.19.21257334.
- 364 18. Schmidt T, Klemis V, Schub D, Mihm J, Hielscher F, Marx S et al. Immunogenicity and reactogenicity  
365 of a heterologous COVID-19 prime-boost vaccination compared with homologous vaccine regimens.  
366 *medRxiv*. 2021:2021.06.13.21258859. doi:10.1101/2021.06.13.21258859.
- 367 19. Liu X, Shaw RH, Stuart ASV, Greenland M, Dinesh T, Provstgaard-Morys S et al. Safety and  
368 Immunogenicity Report from the Com-COV Study – a Single-Blind Randomised Non-Inferiority Trial  
369 Comparing Heterologous And Homologous Prime-Boost Schedules with An Adenoviral Vected and  
370 mRNA COVID-19 Vaccine. SSRN. 2021. doi: <http://dx.doi.org/10.2139/ssrn.3874014>
- 371 20. Neumann F, Rose R, Römpke J, Grobe O, Lorentz T, Fickenscher H et al. Development of SARS-CoV-  
372 2 Specific IgG and Virus-Neutralizing Antibodies after Infection with Variants of Concern or Vaccination.  
373 *Vaccines*. 2021;9(7):700.
- 374 21. Bonelli F, Blocki FA, Bunnell T, Chu E, O ADL, Grenache DG et al. Evaluation of the automated  
375 LIAISON® SARS-CoV-2 TrimericS IgG assay for the detection of circulating antibodies. *Clinical Chemistry*  
376 *and Laboratory Medicine (CCLM)*. 2021;59(8):1463-7. doi:doi:10.1515/cclm-2021-0023.
- 377 22. Kristiansen PA, Page M, Bernasconi V, Mattiuzzo G, Dull P, Makar K et al. WHO International  
378 Standard for anti-SARS-CoV-2 immunoglobulin. *Lancet*. 2021;397(10282):1347-8. doi:10.1016/S0140-  
379 6736(21)00527-4.
- 380 23. Strömer A, Rose R, Grobe O, Neumann F, Fickenscher H, Lorentz T et al. Kinetics of Nucleo- and  
381 Spike Protein-Specific Immunoglobulin G and of Virus-Neutralizing Antibodies after SARS-CoV-2  
382 Infection. *Microorganisms*. 2020;8(10). doi:10.3390/microorganisms8101572.
- 383 24. Frieman M, Harris AD, Herati RS, Krammer F, Mantovani A, Rescigno M et al. SARS-CoV-2 vaccines  
384 for all but a single dose for COVID-19 survivors. *EBioMedicine*. 2021;68.  
385 doi:10.1016/j.ebiom.2021.103401.

386

387